Masoud Maher, President and Chief Executive Officer of MaxCyte, Inc. (NASDAQ:MXCT), has increased his stake in the company with the purchase of 100,000 shares of common stock, according to a regulatory filing. The transaction, dated November 17, 2026, was valued at $120,780 in aggregate.
The shares were acquired at a weighted average price of $1.2078. Individual purchase prices within the transaction ranged from $1.185 to $1.21 per share. Following this acquisition, Maher directly holds 575,000 shares of MaxCyte common stock.
MaxCyte’s stock is currently trading at $1.25, which is slightly above the CEO’s purchase price. According to analysis, the stock appears undervalued, with a Fair Value estimate of $1.31. This insider purchase aligns with a noted tip that management has been aggressively buying back shares—one of seven additional exclusive tips available to subscribers.
The purchase comes on the heels of MaxCyte’s robust third-quarter financial results, which surpassed Wall Street estimates. The company reported revenue of $10.2 million, a 49% increase compared to the same period last year. Adjusted loss per share narrowed to $0.05, better than the anticipated loss of $0.0825 per share.
Stifel reiterated its Buy rating on MaxCyte and maintained a price target of $4.00, highlighting the company’s growth momentum in the third quarter. Instrument demand revenue saw a 100% year-over-year increase, while consumables demand rose by 20%. These developments mark the first year-over-year growth MaxCyte has achieved in eight quarters. The company also shared an expanded outlook for 2026, indicating confidence in its strategic direction.
Insider transactions are closely monitored by investors as they can provide insight into management’s confidence in the company’s prospects. The CEO’s purchase may be viewed as a positive signal, particularly given the recent strong financial performance and analyst support.